Claims for Patent: 7,465,434

Summary for Patent: 7,465,434

Title:	Diagnosis of blood clots using fibrin-binding proteins bound with contrast agents
Abstract:	This invention describes how to modify a fibrin-binding protein, such as tPA, with a contrast agent, such as iodine. This substance could then be given to a patient suspected of having a blood clot by an intravenous route, and then detected by a radiographic study at a short pre-determined time later. Appropriate therapy is started immediately as determined by the radiographic study.
Inventor(s):	Benford; Jacob (Palo Alto, CA)
Assignee:
Application Number:	11/411,256
Patent Claims:	1. A method for detecting a blood clot in a mammalian patient, the method comprising: (a) using a nucleic acid sequence to express a fibrin-binding protein wherein the sequence has been modified to delete a coding sequence that codes for the serine protease domain to remove fibrinolytic activating properties of the fibrin-binding protein; (b) producing a compound comprising the fibrin-binding protein and a contrast agent; (c) introducing the compound into the patient via bolus by an intravenous or intra-arterial insertion; (d) binding the compound to a blood clot; and (e) detecting the compound bound to the blood clot using a radiographic study. 2. The method of claim 1 wherein the fibrin-binding protein comprises: (a) Alteplase; (b) TNK; (c) Reteplase; (d) Streptokinase, or (e) combinations thereof. 3. The method of claim 1 wherein the fibrin-binding protein before modification includes Alteplase. 4. The method of claim 1 wherein the contrast agent includes: (a) Iodine; (b) Gadolinium, or combinations thereof. 5. The method of claim 1 wherein the contrast agent includes iodine. 6. The method of claim 1 wherein the contrast agent includes gadolinium. 7. The method of claim 1 wherein the fibrin-binding protein-contrast agent compound is administered to a human being in an amount between about 0.001 and 100 mg/kg. 8. The method of claim 1 wherein the fibrin-binding protein-contrast agent compound is administered to a human being in an amount between 0.25 and 0.75 mg/kg. 9. The method of claim 1 wherein the mammal is a human being. 10. The method of claim 1 wherein the patient is a human being and the fibrin-binding protein-contrast agent compound is administered to the human being in an amount between about 0.05 and 5 mg/kg. 11. The method of claim 1 wherein detecting the compound occurs about 5-10 minutes after introducing the compound into the patient. 12. The method of claim 1 wherein the radiographic study includes an x-ray. 13. The method of claim 1 wherein the radiographic study includes computed tomography. 14. The method of claim 1 wherein the nucleic acid sequence is a naturally occurring nucleic acid sequence. 15. A method for detecting a blood clot in a mammalian patient, the method comprising: (a) using a nucleic acid to express a fibrin-binding protein wherein a sequence of the nucleic acid has been modified to delete a coding sequence that codes for the serine protease domain to remove fibrinolytic activating properties of the fibrin-binding protein; (b) producing a compound comprising the fibrin-binding protein and a contrast agent; (c) introducing the compound into the patient via bolus by an intravenous or intra-arterial insertion; (d) binding the compound to a blood clot; and (e) detecting the compound bound to the blood clot using a radiographic study.

Details for Patent 7,465,434

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2025-04-25
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2025-04-25
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786	10/30/1996		2025-04-25